AFP and cholangiocarcinoma: Levels of AFP and GAP-TALAD in HCC patients were significantly higher than those in CCA patients and patients with benign liver diseases (p < 0.05), and there were no significant differences in levels of AFP and GAP-TALAD between CCA patients and patients with benign liver diseases (p > 0.05; Table 2, Figs. 2I and 2J).